P-7-1 Effect of strict glycemic control with CSII for 6 years on retinal morphology in diabetic patients

1987 ◽  
Vol 3 ◽  
pp. S62
2007 ◽  
Vol 134 (1) ◽  
pp. 29-37 ◽  
Author(s):  
Cosimo D’Alessandro ◽  
Pascal Leprince ◽  
Jean Louis Golmard ◽  
Alexandre Ouattara ◽  
Stéphane Aubert ◽  
...  

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Ik Jun Choi ◽  
Eun Ho Choo ◽  
Hwa Jung Kim ◽  
Sungmin Lim ◽  
Donggyu Moon ◽  
...  

Abstract Background Intensive glycemic control is generally recommended for diabetic patients to reduce complications. However, the role of glycemic control in the mortality in diabetic patients with acute myocardial infarction (AMI) remained unclear. Methods We selected diabetic patients who measured HbA1c more than 3 times after AMI among 10,719 patients enrolled in the multicenter AMI registry. Patients (n = 1384) were categorized into five groups: according to mean HbA1c level: ≤ 6.5%, > 6.5 to ≤ 7.0%, > 7.0 to ≤ 7.5%, > 7.5 to ≤ 8.0% and > 8.0%. The primary endpoint was all-cause mortality. Results During a median follow-up of 6.2 years, the patients with a mean HbA1c of 6.5 to 7.0% had the lowest all-cause mortality. Compared to patients with mean HbA1c of 6.5 to 7.0%, the risk of all-cause mortality increased in subjects with mean HbA1c ≤ 6.5% (adjusted hazard ratio [HR] 2.00, 95% confidence interval [CI] 1.02–3.95) and in those with mean HbA1c > 8.0% (adjusted HR 3.35, 95% CI 1.78–6.29). In the subgroup analysis by age, the J-curve relationship between mean HbA1c and all-cause mortality was accentuated in elderly patients (age ≥ 65 years), while there was no difference in all-cause mortality across the HbA1c groups in younger patients (age < 65 years). Conclusions The less strict glycemic control in diabetic patients with AMI would be optimal for preventing mortality, especially in elderly patients.


Author(s):  
Arindam Dey ◽  
Unnikrishanan A.G. ◽  
Gaurav Saxena ◽  
Rishi Jain

Diabetic Nephropathy has become the single most import cause of End Stage Renal Disease (ESRD). Various strategies to limit or slow the progress the Diabetic nephropathy are suggested by the guidelines and evidences. By maintaining strict glycemic control the progression of diabetic nephropathy can be altered. Glycemic control in diabetic patients with nephropathy is complex as falling eGFR renders many ant diabetic medications contraindicated while others are needed to be done in low dose. The intent of this review article is to collate the available evidences for renal safety with one such anti diabetic class of medication, dipeptidyl peptidase 4 inhibitor and evaluate the guideline based antidiabetic treatment in Type 2 Diabetes Mellitus patients with renal insufficiency. 


2015 ◽  
Vol 19 (4) ◽  
pp. 179-186
Author(s):  
Altuğ Kut ◽  
Yusuf Boşkuş ◽  
Özgür Çaycı ◽  
Ali Ümit Geçkil

Sign in / Sign up

Export Citation Format

Share Document